These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22818799)

  • 1. Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.
    Boissinot M; Inman M; Hempshall A; James SR; Gill JH; Selby P; Bowen DT; Grigg R; Cockerill PN
    Leuk Res; 2012 Oct; 36(10):1304-10. PubMed ID: 22818799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
    Lu A; Luo H; Shi M; Wu G; Yuan Y; Liu J; Tang F
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4924-7. PubMed ID: 21741834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
    Rajak H; Kumar P; Parmar P; Thakur BS; Veerasamy R; Sharma PC; Sharma AK; Gupta AK; Dangi JS
    Eur J Med Chem; 2012 Jul; 53():390-7. PubMed ID: 22541394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
    Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
    J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
    Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
    Marson CM; Matthews CJ; Atkinson SJ; Lamadema N; Thomas NS
    J Med Chem; 2015 Sep; 58(17):6803-18. PubMed ID: 26287310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
    Rosato RR; Almenara JA; Grant S
    Cancer Res; 2003 Jul; 63(13):3637-45. PubMed ID: 12839953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
    Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
    J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
    Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
    ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Synthesis and anti-tumor activities of N-(aminopyridine) benzamide derivaties].
    Feng J; Li JQ
    Yao Xue Xue Bao; 2009 Dec; 44(12):1376-82. PubMed ID: 21351472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors.
    Stolfa DA; Stefanachi A; Gajer JM; Nebbioso A; Altucci L; Cellamare S; Jung M; Carotti A
    ChemMedChem; 2012 Jul; 7(7):1256-66. PubMed ID: 22628266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group.
    Beckers T; Burkhardt C; Wieland H; Gimmnich P; Ciossek T; Maier T; Sanders K
    Int J Cancer; 2007 Sep; 121(5):1138-48. PubMed ID: 17455259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors.
    Chen Y; He R; Chen Y; D'Annibale MA; Langley B; Kozikowski AP
    ChemMedChem; 2009 May; 4(5):842-52. PubMed ID: 19350613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis.
    Takebe M; Oishi H; Taguchi K; Aoki Y; Takashina M; Tomita K; Yokoo H; Takano Y; Yamazaki M; Hattori Y
    J Surg Res; 2014 Apr; 187(2):559-70. PubMed ID: 24290430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.
    Su H; Yu L; Nebbioso A; Carafa V; Chen Y; Altucci L; You Q
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6284-8. PubMed ID: 19822426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
    Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
    Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.